Tasquinimod

Tasquinimod has anti-angiogenic, antitumor and immune-modulatory properties. It shows consistent anti-angiogenic activity in vitro at doses between 10-50 μM. The mechanism of action of tasquinimod is not clear but may involve inhibition of MDSC action, a key immune checkpoint in cancer, inhibition of the hypoxia-induced angiogenic switch through epigenetic regulation of HDAC3/4 interactions, which may delay metastatic progression and engagement of the S100A9 protein. It is under clinical evaluation for use in combination therapy with other systemic agents in prostate cancer and as a single agent in solid tumors.